Following IPOs by CAR-T players Kite Pharma, Bellicum, Juno Therapeutics and Cellectis totaling over $750 million, CAR-T developer Autolus announced a $150 million IPO, Allogene Therapeutics raised $288 million, and Precision BioSciences filed for $100 Million.
This brings the total value of recent CAR-T IPO’s to nearly $1.3 billion.
Additionally, CAR-T financing rounds have reached nearly $2 billion and there has been nearly $100 billion of market capitalization from the CAR-T companies within recent years.
Clearly, this is a hot market segment and the CAR-T market continues to gain momentum.
CAR-T Market Overview
To track these industry events, BioInformant has released a 33-page CAR-T market brief summarizing all types of investments flowing into CAR-T companies worldwide.
This market brief also features short profiles of 100+ market competitors that are involved with developing CAR-T technologies.
The brief includes the following information:
- Asset agreements
- M&A Activity
- Financing Rounds
- Companies Profiles for 100+ CAR-T Competitors
Use it to:
- Quantify CAR-T industry investments
- Identify well-capitalized companies
- Scout potential partnerships and alliances
- Understand partnerships and co-development programs for CAR-T technologies
- Identify M&A activity within the CAR-T industry
Would you benefit from knowing all CAR-T investments worldwide, including IPOs, financing rounds, acquisitions, partnerships and asset agreements?
With the recent frenzy of CAR-T funding, it’s time for you to take advantage of this rapidly expanding market.
Best of all, for a limited-time, you can claim this data for only $49 (20% off).
Both products will be immediately available for download when you claim them below.
Of course, your investment is backed by a 60-Day Money Back Guarantee.